CureVac Secures Bayer as a Partner for Its Coronavirus Vaccine

1 min read

CureVac (NASDAQ: CVAC) is getting a little help from its fellow German drugmaker Bayer (OTC: BAYR.Y) on the development and potential global launch for its COVID-19 vaccine candidate CVnCoV.

Through the deal, announced today, Bayer will assist CureVac with everything from running clinical trials to gaining regulatory approvals to managing the supply chain. CureVac will be in charge in the EU while Bayer has options to lead the regulatory authorizations in undisclosed areas outside of the EU.

CureVac and Bayer didn’t disclose the financial terms of the deal, so it isn’t clear if CureVac will benefit beyond the ability to sell more vaccine than it could on its own. Even if there’s no up-front payment, the deal still looks like a smart move by CureVac, which is planning on going from no products on the market to supplying hundreds of millions of CVnCoV doses around the world. Bayer, on the other hand, has plenty of experience, having developed drugs for more than a century.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Why Nikola Stock Is Up 10% Today

Next Story

Why Arcturus Therapeutics Stock Skyrocketed Today

Latest from Blog